Market Scope forecasts that the glaucoma surgical device market will grow at a compound annual growth rate (CAGR) of 28.2 percent a year, totaling $1.8 billion by 2022.
Glaucoma is the world’s second leading cause of blindness, and the disease affects more than 80 million people around the globe, according to Market Scope estimates. Diagnosis and treatment are widely available in wealthy nations, but this is not the case in many underdeveloped countries. We estimate that only 32.5 million, or 35.9 percent of individuals with glaucoma, are diagnosed. Of those, only about 713 thousand, or 22 percent, will have surgery. However, newer glaucoma surgical technologies—advanced technology glaucoma surgery (ATGS) drainage devices—offer the promise of safer and more effective outcomes and are already leading to earlier surgical intervention in the treatment paradigm.
ATGS drainage device revenues account for just over half of total market revenues. The largest ATGS category, minimally-invasive glaucoma surgery (MIGS) drainage implants, will account for most of the growth over the next 5 years, but product improvements are also expected in diagnostic devices, pharmaceuticals, lasers, and other surgical devices. MIGS stents are expected to grow at a CAGR of nearly 44 percent, to $1.36 billion by 2022.
Eleven manufacturers of glaucoma surgical products account for roughly 79 percent of all market revenues. The largest of these are Glaukos, Alcon, and New World Medical.
Market Scope published its "2017 Glaucoma Surgical Device Report: A Global Market Analysis for 2016 to 2022" in August 2017. In this report, Market Scope divides the glaucoma surgical device market into four broad categories: conventional glaucoma surgery (CGS) devices, ATGS devices, selective laser trabeculoplasty (SLT) lasers, and disposables/instruments. The report includes market data for 2016, and forecast market performance through 2022.